Inovio Halts Head And Neck Cancer Trial On Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive SummaryFirm prematurely stopped a pivotal oncology study investigating its tumor ablation technology after an independent data monitoring committee raised concerns about adverse events.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.